Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Seventeen patients underwent a thyroid nodule FNAB (results: 12 benign, one follicular neoplasm, three suspicious for malignancy, and one papillary thyroid cancer [PTC]), from which six underwent thyroidectomy; PTC was confirmed by surgical pathology for all cases (8.5% of all nodules observed).
|
31461359 |
2020 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To find an appropriate management strategy for patients with T1bN0M0 PTC, the outcomes of active surveillance for T1bN0M0 to T1aN0M0 PTC were investigated and compared, and the outcomes of surgery for T1bN0M0 PTC were studied.
|
30560718 |
2019 |
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Preoperative cytology samples from 30 cases of histologically-proven PTC-TC and 30 classical PTC controls were selected for this study.
|
30648353 |
2019 |
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We describe a case of papillary thyroid carcinoma with fibromatosis/fasciitis-like stroma (PTC-FLS) that contained the rare BRAF c.1799_1801delTGA (p.V600_K601delinsE) mutation, which has not previously been reported in this tumour, as well as the CTNNB1 c.133T>C (p.S45P) mutation.
|
31327063 |
2019 |
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Papillary thyroid carcinoma (PTC) generally shows an excellent prognosis except in cases with aggressive backgrounds or clinicopathological features.
|
29349484 |
2018 |
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BACKGROUND The aim of this study was to investigate the expression of the BRAF V600E gene mutation and the RET/PTC gene rearrangement in the progression of papillary thyroid carcinoma (PTC) in 50 patients from Inner Mongolia.
|
30254191 |
2018 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FNA = fine-needle aspiration; GEC = gene expression classifier; NIFTP = noninvasive follicular thyroid neoplasm with papillary-like nuclear features; PTC = papillary thyroid cancer; SFN = suspicious for follicular neoplasia.
|
30084677 |
2018 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to evaluate the clinicopathologic characteristics of the MFV-PTC treated in the Yonsei University College of Medicine.Between September 2007 and July 2012, 18,697 patients with PTC were treated in our institution.
|
29489673 |
2018 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
β-cat = β-catenin 1; CI = confidence interval; PTC = papillary thyroid carcinoma; ROC = receiver operating characteristic.
|
29498921 |
2018 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CLN = central lymph node; PTC = papillary thyroid carcinoma; PTMC = papillary thyroid microcarcinoma.
|
30289307 |
2018 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Microscopic examination of CMV-PTC revealed predominately cribriform and morular pattern of cancer cells with characteristic nuclear features of papillary thyroid carcinoma.Psammoma body is rare.
|
28314770 |
2017 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results highlight an important role of <i>miR-195</i> in the initiation and progression of PTC and implicate the potential application of <i>miR-195</i> in PTC target therapy.
|
28740507 |
2017 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparing the cytological or, when performed, histological diagnoses with the results of FNAB-Tg, we found that in 24 cases of lymph node metastases from PTC (19 lymph nodes from patients at the first diagnoses and 5 lymph nodes from PTC patients in follow up) the mean level of Thyroglobulin was 1840.11 ng/ml; range: <0,2 to 11440 ng/ml.
|
28558632 |
2017 |
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Small papillary thyroid cancer (PTC) generally has an excellent prognosis.
|
27732329 |
2017 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discovering the mechanism of PTC genesis and progression and finding new potential diagnostic biomarkers/therapeutic target genes of PTC are of great significance.
|
28673327 |
2017 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCI = Charlson Comorbidity Index; CCR = California Cancer Registry; CI = confidence interval; DTC = differentiated thyroid cancer; FTC = follicular thyroid carcinoma; HCC = Hürthle cell carcinoma; IQR = interquartile range; mPTC = papillary thyroid micro-carcinoma; OR = odds ratio; OSPHD = Office of Statewide Health Planning and Development; PTC = papillary thyroid carcinoma.
|
28816539 |
2017 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FNA = fine-needle aspiration miRNA = micro RNA NGS = next-generation sequencing NIFTP = noninvasive follicular thyroid neoplasm with papillary-like nuclear features NPV = negative predictive value PPV = positive predictive value PTC = papillary thyroid carcinoma RAI = radioactive iodine.
|
28534687 |
2017 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AACE = American Association of Clinical Endocrinologists EFVPTC = encapsulated FVPTC FNA = fine-needle aspiration FVPTC = follicular variant of papillary thyroid carcinoma NIFTP = noninvasive follicular thyroid neoplasm with papillary-like nuclear features PTC = papillary thyroid carcinoma.
|
28920749 |
2017 |
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although PTC-CCV may demonstrate features that overlap with those of the classic variant of PTC, hypercellular smears with papillary structures covered by cells with pseudostratified nuclei that show a paucity of nuclear pseudoinclusions and grooves should alert the cytopathologist to the possibility of this diagnosis.Cancer Cytopathol 2017;125:389-97.© 2017 American Cancer Society.
|
28374549 |
2017 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aims of the current study were to explore plasma lncRNAs as a novel biomarker panel for the diagnosis of non-131I-avid lung metastases of PTC and to investigate the plasma lncRNA expression levels associated with survival in PTC patients with lung metastases.
|
27997908 |
2016 |
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report a FAP-associated CMVPTC tumor with atypically aggressive features harboring a RAS mutation and review the molecular mechanisms associated with this interesting PTC subtype.
|
24702198 |
2014 |
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have developed a home-brew tetracolor break-apart probe able to simultaneously identify the 2 most common genetic alterations in differentiated thyroid carcinoma: RET/PTC variants in papillary thyroid carcinoma and PAX8/PPARg fusion and variants in follicular thyroid carcinoma.
|
24510380 |
2014 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, expression of Sin1 and activation of AKT kinase were analyzed in fresh-frozen tissue samples (normal/tumor), primary cell cultures (papillary thyroid carcinoma [PTC]), and an established thyroid cancer cell line (medullary thyroid carcinoma) by Western blotting.
|
25456951 |
2014 |
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcinoma (MTC and PTC) and cutaneous melanoma and to analyze BRAF(V600E) mutation in plasma and tissues.
|
24858900 |
2014 |
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rearranged during transfection (RET)/papillary thyroid carcinoma (PTC) gene rearrangements are one of the major genetic alterations found in papillary thyroid carcinoma.
|
24957039 |
2014 |